1. Waller SJ, Ratty A, Burbach JPH, Murphy D 1998. Transgenic and transcriptional studies on neurosecretory cell gene expression. Cellular & Molecular Neurobiology 18, 149-171.
2. Iwasaki Y, Oiso Y, Saito H, Majzoub JA 1997. Positive and negative regulation of the rat vasopressin gene promoter. Endocrinology 138, 5266-5274.
3. Russell JA, Leng G 1998. Sex, parturition and motherhood without oxytocin? Journal of Endocrinology 157, 343-359.
4. Carter DA, Murphy D 1991. Rapid changes in poly (A) tail length of vasopressin and oxytocin m RNAs from common early components of neurohypophyseal peptide gene activation following physiological stimulation. Neuroendocrinology 5, 1-6.
5. Mohr E, Kachele I, Mullin C et al. 2002. Rat vasopressin mRNA: a model system to characterize cis-acting elements and trans-acting factors in dendritic mRNA sorting. Progress in Brain Research 139, 211-24.
6. Bichet DG, Arthus M-F, Barjon JN, et al. 1987. Human platelet fraction arginine-vasopressin: Potential physiological role. Journal of Clinical Investigation 79, 881-887.
7. Laycock JF, Hanoune J 1998. From vasopressin receptor to water channel: intracellular traffic, constraint and by-pass. Journal of Endocrinology 159, 361-372.
8. King LS, Yasui M 2002. Aquaporins and disease: lessons from mice to humans. Trends in Endocrinology and Metabolism 13, 355-60.
9. Agre P, King LS, Yasui M et al. 2002. Aquaporin water channels- from atomic structure to clinical medicine. Journal of Physiology 542.1, 3-16.
10. Nielsen S, Kwon T-H, Frokiaer J, Agre P 2007. Regulation and dysregulation of aquaporins in water balance disorders. Journal of Internal Medicine261, 53-64.
11. King LS, Choi M, Fernandez PC, Cartron JP, Agre P 2001. Defective urinary-concentrating ability due to a complete deficiency of aquaporin-1. New England Journal of Medicine 345, 175-179.
12. Ishikawa S, Saito K, Kasono K 2004. Pathological role of aquaporin-2 in impaired water excretion and hyponatraemia. Journal of Neuroendocrinology 16, 293-6.
13. McKenna K, Thompson C 1998. Osmoregulation in clinical disorders of thirst and thirst appreciation. Clinical Endocrinology 49, 139-152.
14. Krigge U, Kjaer A, Kristofferson U et al. 2003. Histamine and prostaglandin interaction in regulation of oxytocin and vasopressin secretion. Journal of Neuroendocrinology 15, 940-5
15. McKinley MJ, Mathai M, McAllen RM et al. 2004. Vasopressin secretion: osmotic and hormonal regulation by the lamina terminalis. Journal of Neuroendocrinology 16, 340-7.
16. Hurbin A, Boisin-Agasse L, Orcel H, Rabie A et al. 1998. The V(1a) and V(1b), but not the V2, vasopressin receptor genes are expressed in the supraoptic nucleus of the rat hypothalamus, and the transcripts are essentially colocalized in the vasopressinergic magnocellular neurons. Endocrinology 139, 4701-4707.
17. Ludwig M 1998. Dendritic release of Vasopressin and Oxytocin. Journal of Neuroendocrinology 10, 881-895.
18. Cunningham JT, Bruno SB, Grindstaff RR et al. 2002. Cardiovascular regulation of supraoptic vasopressin neurons. Progress in Brain Research 139, 257-73.
19. Ishikawa S, Schrier RW 2003. Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clinical Endocrinology 58, 1-17.
20. Young LJ, Nilsen R, Waymire KG et al. 1999. Increased affiliative response to vasopressin in mice expressing the V1a receptor from a monogamous vole. Nature 400, 766-8.
21. Bielsky IF, Hu S-B, Szegda KL et al. 2004. Profound impairment in social recognition and reduction in anxiety-like behaviour in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 29, 483-93.
22. Walum H, Westberg L, Henningsson S et al. 2008. Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans. Proceedings of the National Academy of Sciences USA 105, 14153-14156.
23. Zimmerman EA, Ma L-Y, Nilaver G 1987. Anatomical basis of thirst and vasopressin secretion. Kidney International 32, suppl 21, 514-519.
24. Nishimori K, Young LJ, Guo Q, Wang Z et al. 1996. Oxytocin is required for nursing but is not essential for parturition or reproductive behaviour. Proceedings of the National Academy of Sciences of the USA 93, 11699-11704.
25. Goodwin TM, Valenzuela GJ, Silver H, Creasy G 1996. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Atosiban Study Group. Obstetrics and Gynecology 88, 331-336.
26. Tyzio R, Cossart R, Khalilov I et al. 2006. Maternal Oxytocin Triggers a Transient Inhibitory Switch in GABA Signaling in the Fetal Brain During Delivery. Science 15, 1788-1792.
27. Hammock EAD, Young LJ 2006. Oxytocin, vasopressin and pair bonding: implications for autism. Philosophical Transactions of the Royal Society of London Behavioral and Biological Science 29, 2187–2198.
28. Windle RJ, Gamble LE, Kershaw YM et al. 2006. Gonadal Steroid Modulation of Stress-Induced Hypothalamo-Pituitary-Adrenal Activity and Anxiety Behavior: Role of Central Oxytocin. Endocrinology 147, 2423-2431.
29. Neumann ID, Torner L, N, Veenema AH 2006. Oxytocin actions within the supraoptic and paraventricular nuclei: differential effects on peripheral and intranuclear vasopressin release. American Journal of Physiology 291, R29-R36.
30. Sabatier N 2006. α-Melanocyte-Stimulating Hormone and Oxytocin: A Peptide Signaling Cascade in the Hypothalamus. Journal of Neuroendocrinology 18, 9703 –9710.
31. Seckl JR, Dunger DB, Bevan JS, Nakasu Y, Chowdrey C, Burke CW, Lightman SL 1990. Vasopressin antagonist in early postoperative diabetes insipidus. Lancet 355, 1353-1356.
32. Aghar A , Thornton E et al. 2004. Posterior pituitary dysfunction after traumatic brain injury. Journal of Clinical Endocrinology and Metabolism 89, 5987-5992.
33. Baylis PH, Cheetham T 1998. Diabetes Insipidus. Archives of Disease in Childhood 79, 84-89.
34. Barrett TG, Bundey S 1997. Wolfram (DIDMOAD) syndrome. Journal of Medical Genetics 34, 838–41.
35. Domenecch E, Gomez-Zaera M, Nunes V 2002. WFS1 mutations in spanish patients with diabetes mellitus and deafness. European Journal of Human Genetics 10, 421-6.
36. Cryns K, Sivakumaran TA, Van den Ouweland JMW, et al. 2003. Mutational spectrum of the WFS1 gene in wolfram syndrome, non-syndromic hearing impairment, diabetes mellitus and psychiatric disease. Human Mutation 22, 275-87.
37. Nijenhuis M, van den Akker, ELT, Zalm R et al. 2001. Familial neurohypophyseal diabetes insipidus in a large dutch kindred: effect of the onset of diabetes on growth in children and cell biological defects of the mutant vasopressin prohormone. Journal of Clinical Endocrinology and Metabolism 86, 3410-3420.
38. Ito M, Jameson JL, Ito M 1997. Molecular basis of autosomal dominant Neurohypophyseal Diabetes Insipidus. Cellular toxicity caused by the accumulation of mutant vasopressin precursors within the endoplasmic reticulum. Journal of Clinical Investigation 99, 2897-1905.
39. Siggaard C, Ritig S, Corydon TJ et al. 1999. Clinical and molecular evidence of the abnormal processing and trafficking of the vasopressin preprohormone in a large kindred with familial neurohypophyseal diabetes insipidus due to a signal peptide mutation. Journal of Clinical Endocrinology and Metabolism 84, 2933-2941.
40. Baylis PH 1995. Vasopressin and its Neurophysin. In Endocrinology 3rd edition, Degroot LJ (Ed), Philadelphia USA, WB Saunders.
41. Diederich S, Eckmanns T, Exner P et al. 2001. Differential diagnosis of polyuric/polydipsic syndromes with the aid of urinary vasopressin measurement in adults. Clinical Endocrinology 54, 665-671.
42. Chitturi S, Harris M, Thomsett MJ et al. 2008. Utility of AVP gene testing in familial neurohypophyseal diabetes insipidus. Clinical Endocrinology 69, 926-930.
43. Kurokowa H, Fujisawa I, Nakano Y et al. 1998. Posterior lobe of the pituitary gland; correlation between signal intensity on T1-weighted images and vasopressin concentration. Radiology 207, 79-83.
44. Pivoello R, De Bellis A, Faggiano A et al. 2003. Central diabetes insipidus and autoimmunity: relationship between the occurrence of antibodies to arginine vasopressin-secreting cells and clinical, immunological, and radiological features in a large cohort of patients with central diabetes insipidus of known and unknown etiology. Journal of Clinical Endocrinology and Metabolism 88, 1629-36.
45. Barbieris C, Mouillac B, Durroux T 1998. Structural basis of vasopressin/oxytocin receptor function. Journal of Endocrinology 156, 223-229.
46. Mulders SM, Bichet DG, Rijss JPL et al. 1998. An aquaporin-2 water channel mutant which causes autosomal dominant nephrogenic diabetes insipidus is retained in the golgi complex. Journal of Clinical Investigation 102, 57-66.
47. Adrogue HJ and Madias NE. Hyponatraemia. New England Journal of Medicine 2000; 342: 1581-1589.
48. Whelan B, Bennett K, O’riordan D, Silke B 2009. Serum sodium as a risk factor for in-hospital mortality in acute unselected general medical patients. Quarterly Journal of Medicine 102, 175-182.
49. Verbalis JG 1989. Hyponatremia. In Baylis PH (ed): Water and Salt Homeostasis in Health and Disease. London, Baillière Tindall, pp 499-530.
50. Ball SG, Baylis PH 1998. Mechanisms of drug induced hyponatraemia . Adverse Drug Reaction Bulletin 192, 734-737.
51. Verbalis JG 1994. Pathogenesis of hyponatremia in an experimental model of the syndrome of inappropriate antidiuresis. American journal of Physiology 267, R1617-R1625.
52. Ishikawa S-E, Saito T, Fugagawa A et al. 2001. Close association of urnary excretion of aquaporin-2 with appropriate and inappropriate arginine vasopressin-dependent antidiuresis in hyponatraemia in elderly subjects. Journal of Clinical Endocrinology and Metabolism 86: 1665-1671.
53. Saito T, Higashiyama M, Nakamura T et al. 2001. Urinary excretion of the aquaporin-2 water channel exaggerated in pathological states of impaired water excretion. Clinical Endocrinology 55, 217 - 221.
54. Pedersen RS, Bentzen H, Bech JN et al. 2001. Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans. American Journal of Physiology (Renal Physiology) 280, F860 - 7.
55. Ball SG, Barber T, Baylis PH. Tests of posterior pituitary function. J Endocrinol Invest 2003; 26 (suppl): 15-24
56. Ball SG 2007. Vasopressin and disorders of water balance: the physiology and pathophysiology of vasopressin. Annals of Clinical Biochemistry 44, 417-431.
57. Almond CSD, Shin AY, Fortescue EB et al. 2005. Hyponatraemia among runners in the Boston marathon. New England Journal of Medicine 353, 1550-1556.
58. Siegel AJ, Verbalis JG, Clement S et al. 2007. Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion. Journal of the American Medical Association 120, 461e11-461e17.
59. Feldman BJ, Rosenthal SM, Vargas GA et al. 2005. Nephrogenic syndrome of inappropriate antidiuresis. New England Journal of Medicine 352, 1884-1890.
60. Decaux G, Vandergheynst F, Bouko Y et al. 2007. Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigrNephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. Journal of American Society of Nephrology 18, 606-612.
61. Palmer BF 2003. Hyponatraemia in patients with central nervous system disease: SIADH versus CSW. Trends in Endocrinoogy and Metabolism 14, 182-187.
62. Verbalis JG, Goldsmith SR, Greenberg A et al. 2007. Hyponatraemia treatment guidelines 2007: expert panel recommendations. American Journal of Medicine 120, S1-S21.
63. Schrier RW, Gross P, Gheorghiade M et al. 2006. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatraemia. New England Journal of Medicine 355, 2099-2112.
64. Decaux G, Soupart A, Vassart G 2008. Non-peptide arginine-vasopressin antagonists : the vaptans. Lancet 371, 1624-1632.
65. Ball SG, Vaidja B, Baylis PH 1997. Hypothalamic adipsic syndrome: diagnosis and management. Clinical Endocrinology 47, 405-409.